IMPACT OF PATIENT COST-SHARING ARRANGEMENTS FOR DISEASE MODIFYING THERAPIES ON TREATMENT COMPLIANCE AMONG PATIENTS WITH MULTIPLE SCLEROSIS IN THE UNITED STATES

被引：2
|
作者：
Palmer, L. A. [1 ]
Fowler, R. [1 ]
Shi, N. [2 ]
Dastani, H. [3 ]
Abouzaid, S. [3 ]
Kim, E. [3 ]
机构：
[1] Thomson Reuters, Washington, DC USA
[2] Thomson Reuters, Cambridge, MA USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.527
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A328 / A329
页数：2
相关论文
共 50 条
  • [1] COST-SHARING AND DEMAND ELASTICITY ON DISEASE MODIFYING THERAPIES IN MULTIPLE SCLEROSIS
    Shao, H.
    Shi, L.
    Stoecker, C.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A65 - A65
  • [2] Cost-Sharing and Initiation of Disease-Modifying Therapy for Multiple Sclerosis
    Romley, John
    Goldman, Dana
    Eber, Michael
    Dastani, Home
    Kim, Edward
    Raparla, Swetha
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2012, 18 (08): : 460 - 464
  • [3] Assessment of compliance and patient pathway among multiple sclerosis patients on disease modifying treatment
    Klotild, Matyas
    Tamas, Bobal
    Zsolt, Abonyi
    [J]. IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2023, 76 (9-10): : 309 - 317
  • [4] Prevalence of Treatment Interruptions for Disease Modifying Therapies among Patients with Multiple Sclerosis
    Lublin, F. D.
    Rossi, C.
    Le, H. H.
    Holiday, C.
    Lefebvre, P.
    Pilon, D.
    Keenan, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 201 - 202
  • [5] SPECIALTY TIER COST SHARING AND USE OF DISEASE MODIFYING THERAPIES AMONG MEDICARE BENEFICIARIES WITH MULTIPLE SCLEROSIS
    Doshi, J. A.
    Li, P.
    Yu, X.
    Dahodwala, N. A.
    Chahin, S.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A289 - A289
  • [6] Impact of Patient Cost Sharing on Multiple Sclerosis Treatment
    Palmer, Liisa
    Abouzaid, Safiya
    Shi, Nianwen
    Fowler, Robert
    Lenhart, Greg
    Dastani, Homa
    Kim, Edward
    [J]. AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 : SP28 - SP36
  • [7] Implications of Medicare Part D cost-sharing on disease-modifying therapy initiation among individuals with multiple sclerosis
    Hartung, Daniel M.
    Johnston, Kirbee
    Bourdette, Dennis
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 506 - 506
  • [8] Impact of smoking on treatment response in multiple sclerosis patients receiving disease modifying therapies
    Sequeira, J.
    Rio, J.
    Casellas, A.
    Otero-Romero, S.
    Tintore, M.
    Sastre-Garriga, J.
    Galan, I.
    Comabella, M.
    Nos, C.
    Castillo, J.
    Vidal-Jordana, A.
    Arrambide, G.
    Mulero, P.
    Midaglia, L.
    Rodriguez, B.
    Montalban, X.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 207 - 208
  • [9] Cost of disease-modifying therapies for multiple sclerosis
    Brown, Murray G.
    [J]. NEUROLOGY, 2015, 84 (21) : E181 - E185
  • [10] Economic Impact of Persistence to Disease Modifying Therapies for the Treatment of Multiple Sclerosis
    Szkurhan, Andrea
    Malik, Sarah
    Dembek, Carole
    Agarwal, Sonalee
    Rajagopalan, Kitty
    Rashid, Nazia
    [J]. NEUROLOGY, 2011, 76 (09) : A473 - A473
12345